Clik here to view.
Illumina Cuts Forecasts As Consumer Tests, Genomics Initiatives Lag
About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. It exceeded that goal, with revenue rising 21...
View ArticleClik here to view.
An Entrepreneur’s Quest to Make Seattle a Genome Sciences Hub
Ivan Liachko turned postdoctoral research at the University of Washington into a company whose genomics tools are now found in laboratories researching human, animal, and plant health. His firm, Phase...
View ArticleClik here to view.
UK Regulator Has “Competition Concerns” Over Illumina-PacBio Tie-Up
Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition in the...
View ArticleClik here to view.
Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More
The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them.Amgen (NASDAQ:...
View ArticleClik here to view.
FTC Challenges PacBio Acquisition, Says Illumina is a “Monopolist”
About one year ago Illumina agreed to splash out $1.2 billion on Pacific Biosciences, a rival maker of DNA sequencing technology. Now the Federal Trade Commission is looking to block the deal, and says...
View ArticleClik here to view.
ArcherDX Raises $55M to Help Physicians Pick Best Cancer Therapies
2020 will be a big year for ArcherDX, says its CEO on the heels of raising $55 million to advance its companion diagnostics platform—which is intended to make precision medicine an option for patients...
View ArticleClik here to view.
Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More
As national politics dominates the news in the final days of the decade, we at Xconomy are wrapping up the year with some big moves by the FDA, including an approval of the first drug OK’d reduce heart...
View ArticleClik here to view.
After Antitrust Challenges, Illumina and PacBio Throw in Towel on Merger
DNA sequencing machine maker Illumina will have to find another way to “read” long pieces of genetic material as well as short stretches, the genomic giant’s bailiwick. Its $1.2 billion proposal to...
View ArticleClik here to view.
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More
In the week leading up to Christmas, six drugs won FDA approvals. The decisions covered insomnia, migraine, and several different forms of cancer.The FDA’s final tally for the year totaled 48 new drug...
View ArticleClik here to view.
Vizgen Launches With $14M to Market New Subcellular Imaging Technique
Scientists in a Harvard University lab developed an imaging technique that allows researchers to peer deep into tissue samples to learn more about the molecules and cellular organization within. That...
View ArticleClik here to view.
Flagship Adds $1.1B for New Meds, More AI, &“Health Security”
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.One...
View ArticleClik here to view.
Grail Plants a Seed in RTP, Pledges $100M Investment in New Site
Grail, a clinical-stage company developing cancer tests intended to detect early signs of the disease from a small blood sample, has agreed to invest $100 million in a new outpost planned for Research...
View ArticleClik here to view.
Exec Search Underway at PacBio After CEO, CFO Announce Plans to Retire
Gene sequencing company Pacific Biosciences of California is seeking two new leaders in the wake of retirement announcements by a pair of longtime top executives.PacBio (NASDAQ: PACB) president and CEO...
View ArticleClik here to view.
Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx
Cancer treatment is increasingly moving toward targeted therapies based on the genetics of a patient’s tumor and Invitae is ensuring it gets its share of this growing market with a deal to acquire...
View ArticleClik here to view.
Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More
Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace.Once considered...
View ArticleClik here to view.
Seer Raises $55M to Commercialize Tools to Analyze the Proteome
Illumina led the genomics revolution, developing tools that have changed how scientists discover drugs and how clinicians treat patients. Startup Seer is making the case that its technology for...
View ArticleClik here to view.
Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test
Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to...
View ArticleClik here to view.
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
Grail, a company developing blood tests intended to detect cancer well before symptoms show, is taking its pitch to a broader swath of investors. The diagnostics company is looking ahead to potential...
View ArticleClik here to view.
Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal
[Updated, 3:45 pm ET.] Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years...
View ArticleClik here to view.
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More
In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and...
View Article
